当前位置: 首页 >> 检索结果
81. Effects of physical activity on vascular function in autoimmune rheumatic diseases: a systematic review and meta-analysis.
作者: Tiago Peçanha.;Daniel J Bannell.;Sofia Mendes Sieczkowska.;Nicola Goodson.;Hamilton Roschel.;Victoria S Sprung.;David A Low.
来源: Rheumatology (Oxford). 2021年60卷7期3107-3120页
To summarize existing evidence and quantify the effects of physical activity on vascular function and structure in autoimmune rheumatic diseases (ARDs).
82. Efficacy and safety of multiple intra-articular corticosteroid injections for osteoarthritis-a systematic review and meta-analysis of randomized controlled trials and observational studies.
作者: Shazeen Ayub.;Jaspreet Kaur.;Michelle Hui.;Shima Espahbodi.;Michelle Hall.;Michael Doherty.;Weiya Zhang.
来源: Rheumatology (Oxford). 2021年60卷4期1629-1639页
To investigate the efficacy and safety of multiple intra-articular corticosteroid (IACS) injections for the treatment of OA.
83. Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis.
作者: Sizheng Steven Zhao.;Bradley Pittam.;Nicholas L Harrison.;Ashar E Ahmed.;Nicola J Goodson.;David M Hughes.
来源: Rheumatology (Oxford). 2021年60卷4期1620-1628页
Delay to diagnosis in axial SpA (axSpA) is longer than in many other rheumatic diseases. Prolonged delay is associate with poorer outcomes, including functional impairment and quality of life. Our aims were to describe global variation in delay to diagnosis, factors associated with delay, and delay compared with PsA.
84. CD34+CD133+CD309+ circulating angiogenic cell level is reduced but positively related to hydroxychloroquine use in SLE patients-a case-control study and meta-regression analysis.
作者: Jinghui Huang.;Nien Yee Kow.;Hui Yin Lee.;Anna-Marie Fairhurst.;Anselm Mak.
来源: Rheumatology (Oxford). 2021年60卷8期3936-3944页
To identify and quantify the level of CD34+CD133+CD309+ circulating angiogenic cells (CAC) and explore factors associated with the level of CAC in patients with SLE.
85. Socioeconomic status and occurrence of chronic pain: a meta-analysis.
作者: Jesús Prego-Domínguez.;Zahra Khazaeipour.;Narmeen Mallah.;Bahi Takkouche.
来源: Rheumatology (Oxford). 2021年60卷3期1091-1105页
To examine the association between socioeconomic status (SES) and the occurrence of chronic pain, defined as pain that persists or recurs for >3 months.
86. Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis.
作者: Ilaria Maccora.;Eleonora Fusco.;Edoardo Marrani.;Athimalaipet V Ramanan.;Gabriele Simonini.
来源: Rheumatology (Oxford). 2021年60卷2期568-587页
To summarize evidence regarding efficacy of anti-TNFα in childhood chronic uveitis, refractory to common DMARDs.
87. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
作者: Rudra P Goswami.;Animesh Ray.;Moumita Chatterjee.;Arindam Mukherjee.;Geetabali Sircar.;Parasar Ghosh.
来源: Rheumatology (Oxford). 2021年60卷2期557-567页
To assess the effect of rituximab (RTX) on the lung function parameters in SSc interstitial lung disease (SSc-ILD) patients.
88. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis.
作者: M Guillouard.;N Authier.;B Pereira.;M Soubrier.;S Mathieu.
来源: Rheumatology (Oxford). 2021年60卷2期549-556页
Despite classic analgesic or effective treatments in rheumatic diseases, such as synthetic DMARDs in RA, patients remain in pain and often turn to non-prescribed pharmacological alternatives, such as cannabis self-therapeutic use. However, this medical use of cannabis has not been thoroughly studied.
89. Vitamin D receptor gene polymorphisms and osteoarthritis: a meta-analysis.
作者: Hui-Min Li.;Yi Liu.;Ren-Jie Zhang.;Jing-Yu Ding.;Cai-Liang Shen.
来源: Rheumatology (Oxford). 2021年60卷2期538-548页
To investigate the association of vitamin D receptor (VDR) gene polymorphisms with OA susceptibility.
90. Systematic review and meta-analysis of epidemiological studies on the association of occupational exposure to free crystalline silica and systemic lupus erythematosus.
作者: Alberto Morotti.;Irena Sollaku.;Simona Catalani.;Franco Franceschini.;Ilaria Cavazzana.;Micaela Fredi.;Emma Sala.;Giuseppe De Palma.
来源: Rheumatology (Oxford). 2021年60卷1期81-91页
Some evidence suggests that exposure to free crystalline silica may contribute to the risk of developing SLE. A systematic search was carried out for all published epidemiological studies concerning this association. A meta-analysis was conducted on relevant studies.
91. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis.
作者: José María Pego-Reigosa.;Lindsay Nicholson.;Nick Pooley.;Sue Langham.;Nina Embleton.;Zoe Marjenberg.;Volkan Barut.;Barnabas Desta.;Xia Wang.;Julia Langham.;Edward R Hammond.
来源: Rheumatology (Oxford). 2021年60卷1期60-72页
We conducted a systematic review and meta-analysis to determine the magnitude of infection risk in patients with SLE and evaluate the effect of general and SLE-related factors on infection risk.
92. Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis.
作者: Augusta Ortolan.;Victoria Navarro-Compán.;Alexandre Sepriano.;Robert B M Landewé.;Désirée van der Heijde.;Sofia Ramiro.
来源: Rheumatology (Oxford). 2020年59卷12期3990-3992页 93. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
作者: Désirée van der Heijde.;Robert B M Landewé.;Jürgen Wollenhaupt.;Sander Strengholt.;Ketti Terry.;Kenneth Kwok.;Lisy Wang.;Stanley Cohen.
来源: Rheumatology (Oxford). 2021年60卷4期1708-1716页
Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We evaluated radiographic progression in tofacitinib-treated patients with RA for up to 3 years in two pooled long-term extension (LTE) studies (ORAL Sequel; A3921041) (primary analysis), and for up to 5 years using data integrated from one phase (P)2 (A3921068), two P3 (ORAL Start; ORAL Scan) and two LTE studies (exploratory analysis).
94. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.
作者: Sizheng Steven Zhao.;Selina Robertson.;Tzvi Reich.;Nicolas L Harrison.;Robert J Moots.;Nicola J Goodson.
来源: Rheumatology (Oxford). 2020年59卷Suppl4期iv47-iv57页
Comorbidities are common in people with axial spondyloarthritis (axSpA). In this systematic review and meta-analysis, we aimed to: (i) describe the prevalence of commonly reported comorbidities, (ii) compare comorbidities between axSpA and control populations, and (iii) examine the impact of comorbidity burden on axSpA outcomes.
95. Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis.
作者: Yantao Xu.;Yuting Li.;Mengyuan Dong.;Zi'ang Gao.;Xiang Chen.;Hong Liu.;Minxue Shen.
来源: Rheumatology (Oxford). 2020年59卷12期3657-3665页
We sought to systematically investigate the effectiveness of secukinumab in psoriatic arthritis (PsA) patients who previously received TNFs inhibitor (TNFi) treatment and those who were TNFi naïve.
96. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus.
作者: Alvaro Gomez.;Fawz Hani Butrus.;Petter Johansson.;Emil Åkerström.;Sofia Soukka.;Sharzad Emamikia.;Yvonne Enman.;Susanne Pettersson.;Ioannis Parodis.
来源: Rheumatology (Oxford). 2021年60卷3期1260-1272页
Associations between BMI and health-related quality of life (HRQoL) in SLE have been implied, but data are scarce. We determined the impact of overweight and obesity on HRQoL in a large SLE population.
97. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials.
作者: Alemnew F Dagnew.;Debora Rausch.;Caroline Hervé.;Toufik Zahaf.;Myron J Levin.;Anne Schuind.; .
来源: Rheumatology (Oxford). 2021年60卷3期1226-1233页
In the ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials, the adjuvanted recombinant zoster vaccine (RZV) demonstrated ≥90% efficacy in preventing herpes zoster (HZ) in all age groups ≥50 years. Given the increased HZ risk associated with certain underlying autoimmune diseases or their treatment regimes, we conducted a post hoc analysis of RZV's efficacy against HZ and safety profile [specifically, the occurrence of serious adverse events (SAEs)] in ZOE-50/70 participants who reported pre-existing potential immune-mediated diseases (pIMDs) at enrolment and were not on immunosuppressive therapies.
98. Association of systemic lupus erythematosus with peripheral arterial disease: a meta-analysis of literature studies.
作者: Francesco Forte.;Alessio Buonaiuto.;Ilenia Calcaterra.;Gabriella Iannuzzo.;Pasquale Ambrosino.;Matteo Nicola Dario Di Minno.
来源: Rheumatology (Oxford). 2020年59卷11期3181-3192页
SLE patients have an increased cardiovascular morbidity and mortality. Contrasting data are available about the association between peripheral arterial disease (PAD) and SLE. We aimed to perform a meta-analysis of studies evaluating the association between SLE and PAD.
99. Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis.
作者: Dongze Wu.;Chen Li.;Shuo Zhang.;Priscilla Wong.;Yihan Cao.;James F Griffith.;Xinlu Zhang.;Jieruo Gu.;Lai-Shan Tam.
来源: Rheumatology (Oxford). 2020年59卷11期3172-3180页
To determine the efficacy of biologics in preventing radiographic progression in peripheral joints of PsA patients.
100. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis.
作者: Ana Rita Cruz-Machado.;Santiago Rodrigues-Manica.;Joana Leite Silva.;Irina Alho.;Constança Coelho.;Joana Duarte.;Cláudia Florêncio.;Fernando M Pimentel-Santos.;José Tavares-Costa.;Elsa Vieira-Sousa.
来源: Rheumatology (Oxford). 2020年59卷11期3158-3171页
To assess the efficacy of biologic DMARDs (bDMARDs) in achieving Assessment of Spondyloarthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS-ID), as remission-like surrogates, in axial SpA (axSpA).
|